drugset / Trial / NCT05124951
The Efficacy of WVI in Patients With Localized Basal Ganglia Intracranial Germ Cell Tumors
NaSingle-groupOpen-labelTreatment
Summary
Primary endpoint 1. three-year disease-free survival of patients with localized basal ganglia germ cell tumors receiving whole-ventricle irradiation 2. Health-related quality of life measured by PedsQL 4.0 and SF-36 Second endpoint 1. three-year overall survival of patients with localized basal ganglia germ cell tumors receiving whole-ventricle irradiation 2. Adverse effects of chemoradiotherapy measured by NCI CTCAE 5.0
Timeline
- Start
- 2021-09-15
- Primary completion
- 2026-10-31
- Completion
- 2026-10-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Background | Carboplatin | Small molecule | — | — |
| Background | Cisplatin | Other / unclassified | — | — |
| Background | Etoposide | Small molecule | — | — |
| Background | Ifosfamide | Small molecule | — | — |